Clinical Trials Logo

Heart Transplant Recipients clinical trials

View clinical trials related to Heart Transplant Recipients.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01278745 Terminated - Clinical trials for Cardiac Allograft Vasculopathy

Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan) Therapy in Cardiac Transplantation

Start date: September 2011
Phase: Phase 2
Study type: Interventional

All people who have a heart transplant are at risk for developing cardiac allograft vasculopathy (CAV). CAV means narrowing of the heart transplant vessels, which is associated with poor heart transplant function. People who develop antibodies after transplant have a higher risk of developing CAV. Infections, high cholesterol, and rejection also increase the risk of developing CAV. People who develop CAV usually have to receive another transplant.